Trump’s healthcare plans under contention after Democrats’ midterm landslide
The Democrats have gained significantly more power to contest the Trump administration’s healthcare agenda after the party won the Senate…
04 Nov 2026
Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn
Boehringer Ingelheim has become the latest drugmaker to turn to Sino Biopharmaceutical’s research team, inking a deal worth up to $7.4bn that spans multiple oncology modalities. The license agreement sees…
04 Nov 2026
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera
Pharma giant AbbVie has committed to expanding its UK-based R&D facility in Oxford while separately penning a deal around an inflammatory bowel disease (IBD) asset worth up to $1.37bn with…
04 Nov 2026
GEBRO and Spektus sign collaboration for ActraFlex
Austria-based GEBRO Holding and Canadian company Spektus Pharma have agreed to a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice a day. The pharmaceutical companies did…
04 Nov 2026
FDA to review uniQure’s BLA for Huntington’s gene therapy
The US Food and Drug Administration (FDA) has accepted a biologics licence application (BLA) under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec, an investigational gene therapy to treat…
03 Nov 2026
FDA calls for stronger potency upkeep in CGT manufacturing
Despite moving to loosen certain cell and gene therapy (CGT) quality requirements earlier in the year, the US Food and Drug Administration (FDA) is now tasking manufacturers with placing a…
03 Nov 2026
AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals
AbbVie has announced a licensing agreement with Beijing-based Brise Pharmaceuticals, which will see the pair work together to progress and potentially commercialise a set of early-stage migraine drugs as part…